ArticleApplied radiation oncology2025
Combination of External Beam Radiation Therapy and Immune Checkpoint Inhibitors in Cancer Treatment: Mechanisms, Limitations, and Clinical Applications.
Article in Applied radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
External Beam Radiation Therapy (EBRT) has long been integral in cancer treatment, effectively targeting localized and metastatic tumors. Immunotherapy, especially immune checkpoint inhibitors (ICIs), leverages the immune system to eliminate cancer cells but faces challenges such as treatment resistance. EBRT may provide an approach to overcoming resistance to ICI therapy, thus enhancing ICIs efficacy and broaden their clinical scope. EBRT, by inducing immunogenic cell death primes the immune system and can potentiate ICIs. This combination strategy has shown promise in preclinical studies, highlighting the potential of EBRT to overcome limitations of ICI monotherapy and vice versa. Clinical trials have demonstrated the safety and feasibility of this combination, with evidence suggesting improved tumor control and patient outcomes. Nevertheless, numerous challenges remain. This review explores the mechanisms, challenges, and clinical trials evaluating the combination of EBRT and ICIs, underscoring the need for optimized approaches to maximize clinical efficacy, while minimizing toxicities.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.